Clinical trials: Allogeneic Disease
Hematologic Diseases
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback
The purpose of this study is to determine the safety of a cell therapy, T-allo10, after αβdepleted-HSCT in the hopes that it will boost the adaptive immune reconstitution of the patient while sparing the risk of developing severe…
- Trial name
- NCT04640987
- Testing
- Allogeneic Stem Cell Transplant, CliniMACS Prodigy System, T-allo10 cells addback
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Porteus, Matthew, MD
Abnormal Hematopoiesis, Allogenic Disease
Graft-versus-host Disease Associated Myelosuppression
The objective is to measure the frequency, functionality and phenotype of bone marrow-derived mesenchymal stromal cells in patients after allogeneic hematopoietic stem cell transplantation.
- Conditions
- Abnormal Hematopoiesis, Allogenic Disease, Graft vs Host Disease
- Trial name
- NCT02829216
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Technische Universität Dresden
Sickle Cell Disease
Adding Azathioprine/Hydroxyurea Preconditioning to Alemtuzumab/TBI to Reduce Risk of Graft Failure in MSD HSCT in Adult SCD Patients
In this study the investigators will prospectively investigate whether the addition of a 3-months long preconditioning with azathioprine to the alemtuzumab/TBI non-myeloablative conditioning results in improved disease-free…
- Trial name
- NCT05249452
- Testing
- Preconditioning with azathiprine and hydroxyurea (3 months)
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation
This open label phase-II trial evaluates hematological response of an additional treatment with 5-Azacitidine to common DLI in patients with MDS or AML relapsing after allogeneic stem cell transplantation.
- Trial name
- NCT00795548
- Testing
- 5-Azacitidine
- Where
- 6 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL)
Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant
This study involves the use of a drug called Thymoglobulin, which is approved in the USA to treat kidney transplant rejection and in Canada to treat and to prevent kidney transplant rejection.
- Conditions
- Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Graft vs. Host Disease (GvHD)
- Trial name
- NCT00088543
- Testing
- Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
- Where
- 14 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Genzyme, a Sanofi Company
Lymphoma, B-Cell, Lymphoma, Non-hodgkins
T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
Background: The immune system fights infection and can affect cancer cells. T cells are white blood cells that are a major part of the immune system. T cells can destroy tumors.
- Trial name
- NCT02659943
- Testing
- Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Degenerative Disc Disease
Phase 2a Study on Allogeneic Osteoblastic Cells Implantation in Lumbar Spinal Fusion
Among existing surgical techniques, spinal fusion is considered as the gold standard to treat a broad spectrum of degenerative spine disorders, including spondylolisthesis and scoliosis, with regard to pain reduction and…
- Trial name
- NCT02205138
- Testing
- ALLOB® cells with ceramic scaffold
- Where
- 8 sites in Belgium
- Volunteers
- 38 people
- Sponsor
- Bone Therapeutics S.A
Hematological Diseases
Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases
Determine the efficiency of a myéloablative conditioning associating Fludarabine, Thymoglobuline, and intravenous Busulfan with adapted dose, according to a pharmacokinetics realized in the first day of administration (or J-6 of…
- Trial name
- BX-PK (NCT02483325)
- Testing
- Allogeneic transplant conditioning
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Institut Paoli-Calmettes
Breast Neoplasms
Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer
This Phase 1 trial will investigate the safety of a modified stem cell transplant procedure for treating advanced breast cancer.
- Trial name
- NCT00079625
- Testing
- Th2/Tc2 Cells
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Myeloid, Acute
Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant
This is a Phase 1/2, multicenter, open-label, first-in-human (FIH) study of donor-derived anti-CD33 Chimeric Antigen Receptor (CAR) T cell therapy (VCAR33) in patients with relapsed or refractory Acute Myeloid Leukemia (AML)…
- Trial name
- NCT05984199
- Testing
- VCAR33
- Where
- 14 sites in United States
- Volunteers
- 38 people
- Sponsor
- Vor Biopharma
Cerebral Palsy
Stem Cell and Conditioned Medium for Cerebral Palsy
The aim of this study was to compare the effectiveness of umbilical cord mesenchymal stem cells (UCMSCs) and conditioned medium (CM) administration, UCMSCs only and control with standard therapy.
- Trial name
- NCT04314687
- Testing
- Umbilical Cord Mesenchymal Stem Cells, Conditioned Medium, Standard Therapy
- Where
- Indonesia
- Volunteers
- 78 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Leukemia
CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation
For acute leukemia patients with early relapse after allogeneic stem cell transplantation, the overall outcome is poor. In this study, we evaluate the treatment outcome and safety of chemotherapy with Cladribine, cytarabine and…
- Trial name
- NCT02910752
- Testing
- CLAM+PBSC
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Leukemia, Myeloid, Acute
Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT
The goal of this phase I/II clinical trial is to test in high-risk acute myeloid leukemia (AML) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT).
- Trial name
- NCT05682755
- Testing
- Chidamide
- Where
- China
- Volunteers
- 77 people
- Sponsor
- Sichuan University
Chronic Graft Versus Host Disease, Chronic GVHD
Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
This research study is a Phase I clinical trial, which tests the safety of an investigational combination of IL-2 plus donor anti-inflammatory Treg cells and also tries to define the appropriate dose of the investigational…
- Conditions
- Chronic Graft Versus Host Disease, Chronic GVHD, Complications of Organ Transplant Stem Cells
- Trial name
- NCT01937468
- Testing
- Treg-enriched infusion, Interleukin-2
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Adenovirus Infection, BK Virus Infection
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
This is a Phase 3 study to evaluate posoleucel (ALVR105, Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus…
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- Prevent (NCT05305040)
- Testing
- Posoleucel (ALVR105)
- Where
- 88 sites in United States, Australia and 8 more
- Volunteers
- 451 people
- Sponsor
- AlloVir
Foot Deformities, Acquired, Disorder of Joint of Foot
A Clinical Study of Outcomes in Foot and Ankle Bone Grafting Using map3® Cellular Allogeneic Bone Graft
This is a single arm pilot study in patients requiring surgical fusion in the foot or ankle. Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
- Conditions
- Foot Deformities, Acquired, Disorder of Joint of Foot, Fracture of Foot, Deformity of Bone
- Trial name
- NCT02161016
- Testing
- map3
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- RTI Surgical
Myelodysplastic Syndrome
Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients
Allogeneic blood stem cell transplant remains the only potential curative treatment for myelodysplastic syndromes (MDS) to date.
- Trial name
- NCT01333449
- Testing
- Decitabine
- Where
- Singapore
- Volunteers
- 6 people
- Sponsor
- Singapore General Hospital
Neuromyelitis Optica Spectrum Disorder Relapse
Evaluate the Safety and Tolerability of CE211NS21 in Patients With AQP4-IgG-positive NMOSD Relapse
To evaluate the safety and tolerability of allogeneic bone marrow-derived mesenchymal stem cells (CE211NS21) in patients with severe anti-aquaporin-4-immunoglobulin G positive neuromyelitis optica spectrum disorder…
- Trial name
- NCT07595965
- Testing
- CE211NS21
- Volunteers
- 6 people
- Sponsor
- Corestemchemon, Inc.
Acute Myeloid Leukemia, Myelodysplasia
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia
The primary objective of this study is to examine transplant related mortality (TRM) at 100 days <30%. A TRM of >50% is considered unacceptable.
- Conditions
- Acute Myeloid Leukemia, Myelodysplasia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT00513175
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of California, San Francisco
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
This is a single arm, open-label, Phase 1b study of pembrolizumab for patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) whose disease has relapsed after receiving…
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT03286114
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Michigan Rogel Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.